Drug shortage
Tafamidis Meglumine Capsule · Pfizer Inc.
FDA drug shortage · To Be Discontinued · updated Sep 29, 2025
Key facts
| Generic name | Tafamidis Meglumine Capsule |
|---|---|
| Company | Pfizer Inc. |
| Presentation | Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-8730-30) |
| Dosage form | Capsule |
| Status | To Be Discontinued |
| Therapeutic category | Cardiovascular |
| Package NDCs | 0069-8730-30 |
| First posted | Sep 29, 2025 |
| Last updated | Sep 29, 2025 |
| Discontinued | Sep 29, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: